- Home
- OPCH vs KNSA Comparison
OPCH vs KNSA Comparison
Compare OPCH & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPCH | KNSA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | OPCH | KNSA |
|---|---|---|
| Price | $21.02 | $48.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $36.57 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 3.3M | 457.9K |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.25 | ★ 225.00 |
| EPS | ★ 0.29 | 0.27 |
| Revenue | ★ $4,998,202,000.00 | $677,564,000.00 |
| Revenue This Year | $7.21 | $37.48 |
| Revenue Next Year | $8.55 | $17.87 |
| P/E Ratio | ★ $69.24 | $181.63 |
| Revenue Growth | 16.17 | ★ 60.09 |
| 52 Week Low | $18.01 | $26.27 |
| 52 Week High | $36.80 | $59.87 |
Technical Indicators
Market Signals| Indicator | OPCH | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.02 | 41.82 |
| Support Level | $19.34 | $44.95 |
| Resistance Level | $28.92 | $49.57 |
| Average True Range (ATR) | 0.73 | 1.95 |
| MACD | 0.22 | -0.61 |
| Stochastic Oscillator | 46.32 | 28.17 |
Price Performance
Historical ComparisonAbout OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.